[Report of drug resistance in strains of Mycobacterium tuberculosis isolated from patients in Iran]. 1996

A R Bahrmand, and A Siadati, and G Samar, and A Sanami
Department of Micobacteriology, Pasteur Institute, Tehran-Iran.

6,472 clinical samples of patients with tuberculosis suspicion between March, 1993 and March, 1994, were studied. Positive results were obtained in 443 patients; 238 females (53.7%) and 205 males (46.3%). The predominant age group was that between 30 and 39 years (31.5%). The cutaneous test of sensitivity to the purified protein derivate (PPD) was positive in 178 patients with a range of 10-14 mm. Abnormal radiological images were found in 222 patients (50.1%). Higher resistance frequency was detected in Mycobacterium tuberculosis strains among cases suffering from pulmonary tuberculosis. 42 (9.5%) strains were resistant to isoniazid and 31 (7.0%) to streptomycin. Resistance to one drug was observed in 25 isolations (5.4%). A few strains (1.3%) were resistant to 3 drugs, and 1 of them to 5 drugs. Clinical and epidemiological data suggest that resistance to drugs in tuberculosis is becoming an important problem in the region. The fast diagnosis of this infection and the use of antibiotics with a reduced spectrum may enable the control of this form of tuberculosis.

UI MeSH Term Description Entries
D007492 Iran A country bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan. The capital is Tehran. Islamic Republic of Iran
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D014397 Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung. Pulmonary Consumption,Pulmonary Phthisis,Pulmonary Tuberculoses,Pulmonary Tuberculosis,Tuberculoses, Pulmonary,Consumption, Pulmonary,Consumptions, Pulmonary,Phthises, Pulmonary,Phthisis, Pulmonary,Pulmonary Consumptions,Pulmonary Phthises
D018088 Tuberculosis, Multidrug-Resistant Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS. Tuberculosis, Drug-Resistant,Tuberculosis, MDR,Tuberculosis, Multi-Drug Resistant,Drug-Resistant Tuberculosis,MDR Tuberculosis,Multi-Drug Resistant Tuberculosis,Multidrug-Resistant Tuberculosis,Tuberculosis, Drug Resistant,Tuberculosis, Multi Drug Resistant,Tuberculosis, Multidrug Resistant

Related Publications

A R Bahrmand, and A Siadati, and G Samar, and A Sanami
May 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
A R Bahrmand, and A Siadati, and G Samar, and A Sanami
January 1979, Indian journal of public health,
A R Bahrmand, and A Siadati, and G Samar, and A Sanami
December 1981, Problemy tuberkuleza,
A R Bahrmand, and A Siadati, and G Samar, and A Sanami
November 2001, Microbes and infection,
A R Bahrmand, and A Siadati, and G Samar, and A Sanami
June 2015, Microbial drug resistance (Larchmont, N.Y.),
A R Bahrmand, and A Siadati, and G Samar, and A Sanami
April 2021, Enfermedades infecciosas y microbiologia clinica (English ed.),
A R Bahrmand, and A Siadati, and G Samar, and A Sanami
June 2007, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases,
A R Bahrmand, and A Siadati, and G Samar, and A Sanami
January 2001, Mikrobiolohichnyi zhurnal (Kiev, Ukraine : 1993),
A R Bahrmand, and A Siadati, and G Samar, and A Sanami
January 2014, International journal of molecular and cellular medicine,
Copied contents to your clipboard!